Contrast enhanced oesophageal avoidance for stereotactic body radiotherapy: Barium vs. Gastrografin.

Journal: Technical innovations & patient support in radiation oncology
Published Date: Dec 16, 2019

Abstract

INTRODUCTION: SABR may facilitate treatment in a greater proportion of locally-advanced NSCLC patients, just as it has for early-stage disease. The oesophagus is one of the key dose-limiting organs and visualization during IGRT would better ensure toxicity is avoided. As the oesophagus is poorly seen on CBCT, we assessed the extent to which this is improved using two oral contrast agents.

Authors

  • Katrina Woodford
    Alfred Health Radiation Oncology, The Alfred, Melbourne, Victoria, Australia.
  • Vanessa Panettieri
    Alfred Health Radiation Oncology, The Alfred, Melbourne, Victoria, Australia.
  • Jeremy D Ruben
    Alfred Health Radiation Oncology, The Alfred, Melbourne, Victoria, Australia.
  • Sidney Davis
    Alfred Health Radiation Oncology, The Alfred, Melbourne, Victoria, Australia.
  • Esther Sim
    Alfred Health Radiation Oncology, The Alfred, Melbourne, Victoria, Australia.
  • Trieumy Tran Le
    Alfred Health Radiation Oncology, The Alfred, Melbourne, Victoria, Australia.
  • Sashendra Senthi
    Alfred Health Radiation Oncology, The Alfred, Melbourne, Victoria, Australia.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals